Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2

Fig. 3

miR-26a inhibited EMT process in vivo. a, b HCC subcutaneous tumor tissues (HCCLM3-control, HCCLM3-anti-miR-26a, HepG2-control, and HepG2-miR-26a) were implanted into nude mouse livers to establish the xenograft HCC models. Thirty-five days after implantation, the mice were euthanized, and their body weights and tumor volumes were assessed. c Quantification of bioluminescence of lung metastatic foci showed that down-regulation of miR-26a significantly accelerated pulmonary metastasis (arrows indicate metastatic foci in lung). HCCLM3-anti-miR-26a and HCCLM3-control tumors were compared by both bright field (b) and fluorescence (f) imaging. No pulmonary metastases occurred in HepG2-control xenografts and HepG2-miR-26a (up-regulation miR-26a) xenografts based on quantification of bioluminescence. d Immunohistochemistry revealed that E-cadherin expression was decreased and the expression level of N-cadherin and vimentin was increased in HCCLM3-anti-miR-26a tumors compared to HCCLM3-controls. In HepG2-miR-26a tumors, EMT markers were inhibited compared to HepG2-controls. In addition, EZH2 expression was inversely correlated with expression of E-cadherin in HCCLM3 and HepG2 tumors. Representative images are shown at ×200. *P < 0.05 compared to control

Back to article page